EGF, variants, traits, and what the research shows

EGF - what this gene does

Based on the variants currently on file, EGF (Epidermal Growth Factor) shows associations concentrated in two trait areas: kidney-related conditions and rare disease. No mechanistic or functional details are available from the current dataset; the picture below is drawn entirely from variant-to-trait links.

Key takeaways

• Most variants in this gene on file link to kidney-related traits, with 18 of 20 entries in that category.
• Two variants are linked to rare disease categories rather than kidney.
• All variants carry a uniform magnitude score of 5.50, meaning none stands above the others in evidence weighting.
• No individual effect sizes or sample sizes are available in the current dataset, limiting how precisely the strength of each association can be evaluated.
• These are population-level statistical signals and do not predict any individual outcome.

Notable variants

All 20 variants on file share a magnitude of 5.50. Within the kidney-linked group, rs121434567, rs139266578, rs140319442, rs199756953, rs200400376, rs201101453, and rs368323208 are among those flagged, indicating a broad signal spanning multiple genomic positions. Two variants stand apart by trait category: rs150311153 and rs76275519, which carry rare disease tags rather than kidney, making them the only entries in the current dataset that fall outside the kidney-focused pattern.

Trait associations

The dominant signal across the variant set is kidney-related. Eighteen of the 20 variants on file, including rs121434567, rs139266578, rs140319442, rs140682556, rs141644661, and rs368323208 among others, carry a kidney trait tag. The remaining two, rs150311153 and rs76275519, are tagged to rare disease. No sub-category detail, odds ratios, or sample-size data are available in the current dataset for any of these associations, so the precise nature of the kidney link and the specific rare disease category cannot be characterized further at this time.

Evidence quality

The current evidence base consists of 20 annotated variants, all carrying a uniform magnitude score of 5.50, drawn from a broader set of 291 total variants on file for this gene. No prior SNP summaries, odds ratios (a measure of how much a variant changes the likelihood of a trait), beta coefficients (a measure of effect direction and size in continuous-trait studies), cohort sizes, or replication data are available at this stage. The consistent magnitude score across all entries suggests uniform evidence-weighting treatment, but without underlying study details it is not possible to distinguish multi-cohort replicated findings from single-cohort preliminary signals. The kidney trait theme appearing across 18 independent variant positions provides some internal convergence, but further annotation is needed before any claim about effect direction or clinical relevance can be made.

What this is NOT

These variants are population-level statistical signals derived from GWAS (genome-wide association studies, research designs that scan many people's genomes for variants statistically linked to a trait), not deterministic predictors for any individual. Nothing on this page constitutes a diagnosis, recommendation, or medical advice.